Duodenaladenome und -karzinome: chirurgische Therapiekonzepte

Michael Ghadimi; Jochen Gaedcke

doi:10.1055/a-1911-4200

Onkologie up2date, Table of Contents

Onkologie up2date 2022; 4(04): 325-341
DOI: 10.1055/a-1911-4200

Tumoren des Gastrointestinaltraktes

Duodenaladenome und -karzinome: chirurgische Therapiekonzepte

Authors

Michael Ghadimi
Jochen Gaedcke

Abstract

All articles of this category

Tumoren des Duodenums sind selten und meist Zufallsbefunde der Gastroskopie. Neben den rein benignen Läsionen stellen Veränderungen epithelialen Ursprungs eine relevante Gruppe aufgrund ihres Entartungspotenzials mit dann schlechter Prognose für den Patienten dar. In der Folge sollen diese mit besonderem Schwerpunkt auf den Therapieoptionen beschrieben werden.

Schlüsselwörter

Duodenaladenome - Duodenalkarzinome - ampulläre Adenome - nicht ampulläre Adenome - Therapieoptionen

Full Text

References

Literatur
1 Culver EL, McIntyre AS. Sporadic duodenal polyps: classification, investigation, and management. Endoscopy 2011; 43: 144-155
2 Jepsen JM, Persson M, Jacobsen NO. et al. Prospective study of prevalence and endoscopic and histopathologic characteristics of duodenal polyps in patients submitted to upper endoscopy. Scand J Gastroenterol 1994; 29: 483-487
3 Domenech-Ximenos B, Juanpere S, Serra I. et al. Duodenal tumors on cross-sectional imaging with emphasis on multidetector computed tomography: a pictorial review. Diagn Interv Radiol 2020; 26: 193-199
4 Barat M, Dohan A, Dautry R. et al. Mass-forming lesions of the duodenum: A pictorial review. Diagn Interv Imaging 2017; 98: 663-675
5 Zhang Y, Shi XJ, Zhang XC. et al. Primary duodenal tuberculosis misdiagnosed as tumor by imaging examination: A case report. World J Clin Cases 2020; 8: 6537-6545
6 Gao YP, Zhu JS, Zheng WJ. Brunnerʼs gland adenoma of duodenum: a case report and literature review. World J Gastroenterol 2004; 10: 2616-2617
7 Bilimoria KY, Bentrem DJ, Wayne JD. et al. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg 2009; 249: 63-71
8 Miettinen M, Kopczynski J, Makhlouf HR. et al. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases. Am J Surg Pathol 2003; 27: 625-641
9 Akazawa Y, Ueyama H, Tsuyama S. et al. Endoscopic and Clinicopathological Features of Superficial Non-Ampullary Duodenal Tumor Based on the Mucin Phenotypes. Digestion 2021; 102: 663-670
10 Johnson MD, Mackey R, Brown N. et al. Outcome based on management for duodenal adenomas: sporadic versus familial disease. J Gastrointest Surg 2010; 14: 229-235
11 Pavlovic-Markovic A, Dragasevic S, Krstic M. et al. Assessment of Duodenal Adenomas and Strategies for Curative Therapy. Dig Dis 2019; 37: 374-380
12 Spigelman AD, Williams CB, Talbot IC. et al. Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Lancet 1989; 2: 783-785
13 Okada K, Fujisaki J, Kasuga A. et al. Sporadic nonampullary duodenal adenoma in the natural history of duodenal cancer: a study of follow-up surveillance. Am J Gastroenterol 2011; 106: 357-364
14 Buchbjerg T, Fristrup C, Mortensen MB. The incidence and prognosis of true duodenal carcinomas. Surg Oncol 2015; 24: 110-116
15 Anand U, Pandey MK, Priyadarshi RN. et al. Large Tubullo-villous Adenoma of Duodenum Presenting as Gastric Outlet Obstruction. J Clin Diagn Res 2015; 9: PD03-PDD04
16 Spira IA, Wolff WI. Villous tumors of the duodenum. Am J Gastroenterol 1977; 67: 63-68
17 Vanbiervliet G, Strijkeer M, Arvanitakis M. et al. Endoscopic management of ampullary tumors: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2021; 53: 429-448
18 Vanbiervliet G, Moss A, Arvanitakis M. et al. Endoscopic management of superficial nonampullary duodenal tumors: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2021; 53: 522-534
19 Suwa T, Takizawa K, Kawata N. et al. Current Treatment Strategy for Superficial Nonampullary Duodenal Epithelial Tumors. Clin Endosc 2022; 55: 15-21
20 Blanco-Fernández G, Rojas-Holguín A, De-Armas-Conde N. et al. Side-to-side duodenojejunostomy after resection of third and fourth duodenal portions with pancreatic preservation. Updates Surg 2020; 72: 1105-1113
21 Hashimoto D, Arima K, Chikamoto A. et al. Limited Resection of the Duodenum for Nonampullary Duodenal Tumors, with Review of the Literature. Am Surg 2016; 82: 1126-1132
22 Walsh RM, Augustin T, Aleassa EM. et al. Comparison of pancreas-sparing duodenectomy (PSD) and pancreatoduodenectomy (PD) for the management of duodenal polyposis syndromes. Surgery 2019; 166: 496-502
23 Ganschow P, Hackert T, Biegler M. et al. Postoperative outcome and quality of life after surgery for FAP-associated duodenal adenomatosis. Langenbecks Arch Surg 2018; 403: 93-102
24 di Mola FF, Panaccio P, Grottola T. et al. Transduodenal surgical ampullectomy: a procedure that requires a multidisciplinary approach. Updates Surg, 2021.
25 Schneider M, Büchler WW. [Ampullary neoplasms: surgical management]. Chirurg 2021; 92: 796-802
26 Schneider L, Contin P, Fritz S. et al. Surgical ampullectomy: an underestimated operation in the era of endoscopy. HPB (Oxford) 2016; 18: 65-71
27 Papalampros A, Moris D, Petrou A. et al. Non-Whipple Operations in the Management of Benign, Premalignant and Early Cancerous Duodenal Lesions. Anticancer Res 2017; 37: 1443-1452
28 Nappo G, Gentile D, Galvanin J. et al. Trans-duodenal ampullectomy for ampullary neoplasms: early and long-term outcomes in 36 consecutive patients. Surg Endosc 2020; 34: 4358-4368
29 Linn YL, Wang Z, Goh BKP. Robotic transduodenal ampullectomy: Case report and review of the literature. Ann Hepatobiliary Pancreat Surg 2021; 25: 150-154
30 Khan AS, Siddiqui I, Affleck A. et al. Robotic Surgery for Benign and Low-Grade Malignant Diseases of the Duodenum. Am Surg 2019; 85: 414-419
31 Mitchell WK, Thomas PF, Zaitoun AM. et al. Pancreas preserving distal duodenectomy: A versatile operation for a range of infra-papillary pathologies. World J Gastroenterol 2017; 23: 4252-4261
32 Köninger J, Friess H, Wagner M. et al. [Technique of pancreas-preserving duodenectomy]. Chirurg 2005; 76: 273-281
33 Imamura M, Komoto I, Doi R. et al. New pancreas-preserving total duodenectomy technique. World J Surg 2005; 29: 203-207
34 Jung YK, Paik SS, Choi D. et al. Transduodenal ampullectomy for ampullary tumor. Asian J Surg 2021; 44: 723-729
35 Hollenbach M, Abou Ali E, Auriemma F. et al. Study Protocol of the ESAP Study: Endoscopic Papillectomy vs. Surgical Ampullectomy vs. Pancreaticoduodenectomy for Ampullary Neoplasm – A Pancreas2000/EPC Study. Front Med (Lausanne) 2020; 7: 152
36 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). https://www.leitlinienprogramm-onkologie.de/leitlinien/pankreaskarzinom/%22%3ehttps://www.leitlinienprogramm-onkologie.de/leitlinien/pankreaskarzinom/%3c/uri%3e
37 Saluja SS, Mishra PK, Kiran S. et al. Impact of lymph node staging systems in predicting outcome in patients with ampullary cancer. Ann Hepatobiliary Pancreat Surg 2020; 24: 484-495
38 Lee JW, Choi SB, Lim TW. et al. Prognostic value of the lymph node metastasis in patients with ampulla of Vater cancer after surgical resection. Ann Hepatobiliary Pancreat Surg 2021; 25: 90-96
39 Staerkle RF, Vuille-Dit-Bille RN, Soll C. et al. Extended lymph node resection versus standard resection for pancreatic and periampullary adenocarcinoma. Cochrane Database Syst Rev 2021; (01) CD011490
40 Netherlands Trial Registry. NTR ID NL8424. Im Internet (Stand: 02.05.2022): http://www.trialregister.nl%22%3ehttp://www.trialregister.nl
41 Zimmermann C, Wolk S, Aust DE. et al. The pathohistological subtype strongly predicts survival in patients with ampullary carcinoma. Sci Rep 2019; 9: 12676
42 Nappo G, Galvanin J, Gentile G. et al. Long-term outcomes after pancreatoduodenectomy for ampullary cancer: The influence of the histological subtypes and comparison with the other periampullary neoplasms. Pancreatology 2021; 21: 950-956
43 Park SH, Shin JH, Jung KU. et al. Prognostic value of carcinoembryonic antigen and carbohydrate antigen 19-9 in periampullary cancer patients receiving pancreaticoduodenectomy. Asian J Surg 2021; 44: 829-835
44 Moekotte AL, Malleo G, van Roessel S. et al. Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study. Br J Surg 2020; 107: 1171-1182
45 Bolm L, Ohrner K, Nappo G. et al. Adjuvant therapy is associated with improved overall survival in patients with pancreatobiliary or mixed subtype ampullary cancer after pancreatoduodenectomy – A multicenter cohort study. Pancreatology 2020; 20: 433-441
46 Neoptolemos JP, Moore MJ, Cox TF. et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs. observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA 2012; 308: 147-156
47 Chandrasegaram MD, Gill AJ, Samra J. et al. Ampullary cancer of intestinal origin and duodenal cancer – A logical clinical and therapeutic subgroup in periampullary cancer. World J Gastrointest Oncol 2017; 9: 407-415
48 Kamarajah SK, Bednar F, Cho CS. et al. Survival Benefit of Adjuvant Chemotherapy After Pancreatoduodenectomy for Ampullary Adenocarcinoma: a Propensity-Matched National Cancer Database (NCDB) Analysis. J Gastrointest Surg 2021; 25: 1805-1814
49 Patel M, Uboha NV. Treatment Approach to Adenocarcinoma of the Ampulla of Vater. Curr Treat Options Oncol 2021; 22: 103
50 ClinicalTrials.gov. Phase III Trial Investigating the Potential Benefit of Adjuvant Chemotherapy for Small Bowel Adenocarcinoma (BALLAD). Im Internet (Stand: 02.05.2022): https://clinicaltrials.gov/ct2/show/study/NCT02502370